Novo Nordisk Research Center Indianapolis, Inc. (NNRCII) was established in late 2015 when Novo Nordisk acquired Calibrium and MB2, two private companies co-founded by Dr. Richard DiMarchi that were focused on developing peptide-based drug candidates for treatment of diabetes and obesity. Today, NNRCII is the home of an elite research team working in unison within Novo Nordisk’s global research mission to transform the management of cardio-metabolic diseases.
Our scientists are focused on innovative discovery projects
pertaining to diabetes, obesity and related diseases. We develop and
employ cutting-edge biotechnologies to identify, refine, and select
suitable drug candidates that possess novel mechanisms of biological
action through collaboration with internationally acclaimed academic
centers of excellence.